Natera, Inc. (NASDAQ:NTRA) Position Increased by Wellington Management Group LLP

Wellington Management Group LLP lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 15.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,240,041 shares of the medical research company's stock after acquiring an additional 439,778 shares during the period. Wellington Management Group LLP owned 2.40% of Natera worth $512,898,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after purchasing an additional 97 shares during the last quarter. Versant Capital Management Inc boosted its position in Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock worth $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares during the last quarter. Principal Securities Inc. grew its stake in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock worth $57,000 after purchasing an additional 332 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Remove Ads

Natera Stock Down 3.5 %

Shares of NASDAQ NTRA traded down $4.84 on Friday, hitting $133.87. The company had a trading volume of 3,247,142 shares, compared to its average volume of 1,377,854. The business has a 50 day moving average of $156.81 and a two-hundred day moving average of $151.40. The firm has a market capitalization of $18.10 billion, a P/E ratio of -76.06 and a beta of 1.80. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 12-month low of $83.13 and a 12-month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the transaction, the chief executive officer now owns 267,629 shares of the company's stock, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of Natera stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $140.48, for a total value of $421,440.00. Following the completion of the transaction, the insider now owns 141,782 shares of the company's stock, valued at $19,917,535.36. This trade represents a 2.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 325,922 shares of company stock worth $51,603,664. 7.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on NTRA shares. Morgan Stanley lifted their price objective on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. JPMorgan Chase & Co. upped their price objective on shares of Natera from $160.00 to $200.00 and gave the company an "overweight" rating in a research note on Friday, December 13th. Barclays initiated coverage on shares of Natera in a report on Thursday, January 23rd. They set an "overweight" rating and a $200.00 price objective on the stock. The Goldman Sachs Group boosted their target price on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. Finally, Robert W. Baird increased their price target on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus target price of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.